Cue Biopharma (CUE) vs MediWound (MDWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed MediWound (MDWD) over the past year, losing 0.2% versus a loss of 26.7%. Over five years, MDWD leads with a -46.2% price change compared with -94.0% for CUE. MediWound is the larger company by market cap ($165.9 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | MDWD |
|---|---|---|
| Share price | $22.51 | $12.85 |
| Market cap | $163.52M | $165.90M |
| 1-day change | -2.72% | -2.28% |
| YTD return | +146.01% | -30.39% |
| 1-year return | -0.22% | -26.74% |
| 5-year return | -94.04% | -46.17% |
| EPS (TTM) | $-28.75 | $-2.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $20.03 |
| 52-week low | $4.98 | $12.52 |
| Distance from 52-week high | -50.53% | -35.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +290.94% | +138.68% |
| Average volume | 269.82K | 84.20K |
| Shares outstanding | 7.26M | 12.91M |
| Employees | 29 | 121 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed MDWD by 26.5 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Healthcare · Biotechnology · 121 employees
CUE vs MDWD FAQ
Which is bigger, Cue Biopharma or MediWound?
MediWound (MDWD) is larger, with a market capitalization of $165.90M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or MDWD?
CUE returned -0.22% over the past 12 months, compared with -26.74% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and MediWound in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.